New antibiotics against gram-positives: Present and future indications

Current Opinion in Pharmacology

Volumn 24, Issue , 2015, Pages 45-51

  Morata, Laura ^a   Mensa, Josep ^a   Soriano, Alex ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; DALBAVANCIN; LIPOGLYCOPEPTIDE DERIVATIVE; NEW DRUG; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; TEDIZOLID; TELAVANCIN; UNCLASSIFIED DRUG; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; GLYCOPEPTIDE; OXAZOLE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; BACTERIAL SKIN DISEASE; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; EUROPE; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INFECTIOUS PNEUMONIA; METALLIC TASTE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; VOMITING; ANIMAL; GRAM-POSITIVE BACTERIAL INFECTIONS;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLES;

EID: 84938055144     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.07.004     Document Type: Review

References (61)

1. V.G. Fowler, J.M. Miro, B. Hoen, C.H. Cabell, E. Abrutyn, E. Rubinstein, G.R. Corey, D. Spelman, S.F. Bradley, B. Barsic, and et al. Staphylococcus aureus endocarditis: a consequence of medical progress JAMA 293 2005 3012 3021
2. S.J. Kim, L. Cegelski, D. Stueber, M. Singh, E. Dietrich, K.S.E. Tanaka, T.R. Parr, A.R. Far, and J. Schaefer Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus J Mol Biol 377 2008 281 293
3. A. Belley, G.A. McKay, F.F. Arhin, I. Sarmiento, S. Beaulieu, I. Fadhil, T.R. Parr, and G. Moeck Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing Antimicrob Agents Chemother 54 2010 5369 5371
4. N.E. Allen, and T.I. Nicas Mechanism of action of oritavancin and related glycopeptide antibiotics FEMS Microbiol Rev 26 2003 511 532
5. L.D. Saravolatz, G.E. Stein, and L.B. Johnson Telavancin: a novel lipoglycopeptide Clin Infect Dis 49 2009 1908 1914
6. R.E. Mendes, D.J. Farrell, H.S. Sader, and R.N. Jones Oritavancin microbiologic features and activity results from the surveillance program in the United States Clin Infect Dis 54 2012 S203 S213
7. D.J. Biedenbach, J.M. Bell, H.S. Sader, J.D. Turnidge, and R.N. Jones Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates Antimicrob Agents Chemother 53 2009 1260 1263
8. M.E. Stryjewski, D.R. Graham, S.E. Wilson, W. O'Riordan, D. Young, A. Lentnek, D.P. Ross, V.G. Fowler, A. Hopkins, H.D. Friedland, and et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms Clin Infect Dis 46 2008 1683 1693
9. E. Rubinstein, T. Lalani, G.R. Corey, Z.A. Kanafani, E.C. Nannini, M.G. Rocha, G. Rahav, M.S. Niederman, M.H. Kollef, A.F. Shorr, and et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens Clin Infect Dis 52 2011 31 40
10. C.M. Rubino, S.M. Bhavnani, G. Moeck, S.E. Bellibas, and P.G. Ambrose Population pharmacokinetic analysis for a single 1200 mg dose of oritavancin using data from two pivotal phase 3 clinical trials Antimicrob Agents Chemother 59 2015 3365 3372
11. P.G. Ambrose, G.L. Drusano, and W.A. Craig In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans Clin Infect Dis 54 2012 S220 S228
12. B. Baquir, S. Lemaire, F. Van Bambeke, P.M. Tulkens, L. Lin, and B. Spellberg Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin Clin Infect Dis 54 2012 S229 S232
13. A. Belley, E. Neesham-Grenon, G. McKay, F.F. Arhin, R. Harris, T. Beveridge, T.R. Parr, and G. Moeck Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro Antimicrob Agents Chemother 53 2009 918 925
14. S. Gander Telavancin: in vitro activity against staphylococci in a biofilm model J Antimicrob Chemother 56 2005 337 343
15. H.A. Nguyen, O. Denis, A. Vergison, A. Theunis, P.M. Tulkens, M.J. Struelens, and F. Van Bambeke Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains Antimicrob Agents Chemother 53 2009 1434 1442
16. H.A. Nguyen, O. Denis, A. Vergison, P.M. Tulkens, M.J. Struelens, and F. Van Bambeke Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations Antimicrob Agents Chemother 53 2009 1443 1449
17. G.R. Corey, H. Kabler, P. Mehra, S. Gupta, J.S. Overcash, A. Porwal, P. Giordano, C. Lucasti, A. Perez, S. Good, and et al. Single-dose oritavancin in the treatment of acute bacterial skin infections N Engl J Med 370 2014 2180 2190
18. E. Seltzer, M.B. Dorr, B.P. Goldstein, M. Perry, J.A. Dowell, T. Henkel Dalbavancin Skin and Soft-Tissue Infection Study Group Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections Clin Infect Dis 37 2003 1298 1303
19. H.W. Boucher, M. Wilcox, G.H. Talbot, S. Puttagunta, A.F. Das, and M.W. Dunne Once-weekly dalbavancin versus daily conventional therapy for skin infection N Engl J Med 370 2014 2169 2179
20. I. Raad, R. Darouiche, J. Vazquez, A. Lentnek, R. Hachem, H. Hanna, B. Goldstein, T. Henkel, and E. Seltzer Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens Clin Infect Dis 40 2005 374 380
21. S.M. Bhavnani, J.A. Passarell, J.S. Owen, J.S. Loutit, S.B. Porter, and P.G. Ambrose Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia Antimicrob Agents Chemother 50 2006 994 1000
22. K.W. McConeghy, S.C. Bleasdale, and K.A. Rodvold The empirical combination of vancomycin and a B-lactam for staphylococcal bacteremia Clin Infect Dis 57 2013 1760 1765
23. H. Moisan, M. Pruneau, and F. Malouin Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae J Antimicrob Chemother 65 2010 713 716
24. T.A. Davies, M.G.P. Page, W. Shang, T. Andrew, M. Kania, and K. Bush Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae Antimicrob Agents Chemother 51 2007 2621 2624
25. L.D. Saravolatz, G.E. Stein, and L.B. Johnson Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus Clin Infect Dis 52 2011 1156 1163
26. H.S. Sader, R.K. Flamm, J.M. Streit, D.J. Farrell, and R.N. Jones Ceftaroline activity against bacterial pathogens frequently isolated in U.S. Medical Centers: results from five years of the AWARE surveillance program Antimicrob Agents Chemother 59 2015 2458 2461
27. S.D. Anderson, and J.G. Gums Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin Ann Pharmacother 42 2008 806 816
28. E.C. Nannini, M.E. Stryjewski, K.V. Singh, T.H. Rude, G.R. Corey, V.G. Fowler, and B.E. Murray Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus Antimicrob Agents Chemother 54 2010 2206 2208
29. D.G. Lee, Y. Murakami, D.R. Andes, and W.A. Craig Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 105 and 107 CFU injected into opposite thighs of neutropenic mice Antimicrob Agents Chemother 57 2013 1434 1441
30. Y.P. Chong, S.-J. Park, H.S. Kim, E.S. Kim, M.-N. Kim, S.H. Kim, S.-O. Lee, S.-H. Choi, J.-Y. Jeong, J.H. Woo, and et al. In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC Diagn Microbiol Infect Dis 73 2012 264 266
31. T.P. Lodise, R. Pypstra, J.B. Kahn, B.P. Murthy, H.C. Kimko, K. Bush, G.J. Noel, and G.L. Drusano Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects Antimicrob Agents Chemother 51 2007 2378 2387
32. G.G. Zhanel, D. Voth, K. Nichol, J.A. Karlowsky, A.M. Noreddin, and D.J. Hoban Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model J Antimicrob Chemother 64 2009 364 369
33. A.E. Muller, N. Punt, and J.W. Mouton Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia Antimicrob Agents Chemother 58 2014 2512 2519
34. G.J. Noel, K. Bush, P. Bagchi, J. Ianus, and R.S. Strauss A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections Clin Infect Dis 46 2008 647 655
35. S.C. Nicholson, T. Welte, T.M. File, R.S. Strauss, B. Michiels, P. Kaul, D. Balis, D. Arbit, K. Amsler, and G.J. Noel A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation Int J Antimicrob Agents 39 2012 240 246
36. S.S. Awad, A.H. Rodriguez, Y.C. Chuang, Z. Marjanek, A.J. Pareigis, G. Reis, T.W.L. Scheeren, A.S. Sanchez, X. Zhou, M. Saulay, and et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia Clin Infect Dis 59 2014 51 61
37. W. So, J.L. Crandon, G.G. Zhanel, and D.P. Nicolau Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of ceftaroline fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter Antimicrob Agents Chemother 58 2014 6931 6933
38. K.E. Barber, B.J. Werth, C.E. Ireland, N.E. Stone, P. Nonejuie, G. Sakoulas, J. Pogliano, and M.J. Rybak Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes J Antimicrob Chemother 69 2014 3006 3010
39. K.E. Barber, B.J. Werth, and M.J. Rybak The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA J Antimicrob Chemother 70 2015 505 509
40. G. Sakoulas, P.A. Moise, A.M. Casapao, P. Nonejuie, J. Olson, C.Y.M. Okumura, M.J. Rybak, R. Kullar, A. Dhand, W.E. Rose, and et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline Clin Ther 36 2014 1317 1333
41. S.M. Bhavnani, J.P. Hammel, S.A. Van Wart, C.M. Rubino, D.K. Reynolds, A. Forrest, G.L. Drusano, T. Khariton, H.D. Friedland, T.A. Riccobene, and et al. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections Antimicrob Agents Chemother 59 2014 372 380
42. G.R. Corey, M. Wilcox, G.H. Talbot, H.D. Friedland, T. Baculik, G.W. Witherell, I. Critchley, A.F. Das, and D. Thye Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection Clin Infect Dis 51 2010 641 650
43. T.M. File, D.E. Low, P.B. Eckburg, G.H. Talbot, H. David Friedland, J. Lee, L. Llorens, I. Critchley, and D. Thye Integrated analysis of FOCUS 1 and FOCUS 2 randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia Clin Infect Dis 51 2010 1395 1405
44. S.M. Bhavnani, J.P. Hammel, S.A. Van Wart, C.M. Rubino, D.K. Reynolds, A. Forrest, T. Khariton, H.D. Friedland, T.A. Riccobene, and P.G. Ambrose Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia Antimicrob Agents Chemother 57 2013 6348 6350
45. N.S. Zhong, T. Sun, Ch. Zhou, G. D'Souza, S.H. Lee, N.H. Lan, Ch. Chiang, D. Wilson, F. Sun, J. Iaconis, and et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial Lancet Infect Dis 15 2015 161 171
46. R.G. Wunderink, M.S. Niederman, M.H. Kollef, A.F. Shorr, M.J. Kunkel, A. Baruch, W.T. McGee, A. Reisman, and J. Chastre Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study Clin Infect Dis 54 2012 621 629
47. M.E. Falagas, I.I. Siempos, and K.Z. Vardakas Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials Lancet Infect Dis 8 2008 53 66
48. E. Senneville, L. Legout, M. Valette, Y. Yazdanpanah, F. Giraud, E. Beltrand, G. Obert, L. Dubreuil, H. Migaud, and Y. Mouton Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study J Antimicrob Chemother 54 2004 798 802
49. M.S. García, M.A. la Torre De, G. Morales, B. Peláez, M.J. Tolón, S. Domingo, F.J. Candel, R. Andrade, A. Arribi, N. García, and et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit JAMA 303 2010 2260 2264
50. C. Betriu, G. Morales, I. Rodríguez-Avial, E. Culebras, M. Gómez, F. López-Fabal, and J.J. Picazo Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain Antimicrob Agents Chemother 54 2010 2212 2215
51. J.B. Locke, G.E. Zurenko, K.J. Shaw, and K. Bartizal Tedizolid for the management of human infections: in vitro characteristics Clin Infect Dis 58 Suppl 1 2014 S35 S42
52. J.B. Locke, J. Finn, M. Hilgers, G. Morales, S. Rahawi, G.C.K. Picazo, J.J. Im, W. Shaw, and K.J.J.L. Stein Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations Antimicrob Agents Chemother 54 2010 5337 5343
53. J.B. Locke, D.E. Zuill, C.R. Scharn, J. Deane, D.F. Sahm, G.A. Denys, R.V. Goering, and K.J. Shaw Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene Antimicrob Agents Chemother 58 2014 6592 6598
54. I. Rodríguez-Avial, E. Culebras, C. Betriu, G. Morales, I. Pena, and J.J. Picazo In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci J Antimicrob Chemother 67 2012 167 169
55. K.J. Shaw, S. Poppe, R. Schaadt, V. Brown-Driver, J. Finn, C.M. Pillar, D. Shinabarger, and G. Zurenko In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains Antimicrob Agents Chemother 52 2008 4442 4447
56. O. Urbina, O. Ferrández, M. Espona, E. Salas, I. Ferrández, and S. Grau Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections Drug Des Devel Ther 7 2013 243 265
57. T.P. Lodise, and G.L. Drusano Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate Clin Infect Dis 58 Suppl 1 2014 S28 S34
58. G.L. Drusano, W. Liu, R. Kulawy, and A. Louie Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model Antimicrob Agents Chemother 55 2011 5300 5305
59. S. Flanagan, J. Passarell, Q. Lu, J. Fiedler-Kelly, E. Ludwig, and P. Prokocimer Tedizolid population pharmacokinetics, exposure-response, and target attainment Antimicrob Agents Chemother 58 2014 6462 6470
60. S. Flanagan, S.L. Minassian, D. Morris, R. Ponnuraj, T.C. Marbury, H.W. Alcorn, E. Fang, and P. Prokocimer Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment Antimicrob Agents Chemother 58 2014 6471 6476
61. A.F. Shorr, T.P. Lodise, G.R. Corey, C. De Anda, E. Fang, A.F. Das, and P. Prokocimer Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections Antimicrob Agents Chemother 59 2015 864 871